SEC Filing Summary: PharmAthene, Inc. (Form 8-K)
Business Context and Reporting Period
Date: August 3, 2007
Company: PharmAthene, Inc. (formerly Healthcare Acquisition Corp. or "HAQ")
Event: Consummation of a reverse merger with Former PharmAthene, Inc.
Context: HAQ, previously a blank check company with no operations, merged with Former PharmAthene to become an operating biotechnology company. Immediately following the merger, HAQ changed its name to PharmAthene, Inc., and Former PharmAthene became a wholly-owned subsidiary named PharmAthene US Corporation. The company is headquartered in Annapolis, Maryland.
Key Financial Metrics and Transaction Consideration
Transaction Consideration:
- Stock Consideration: 12,500,000 shares of common stock issued to Former PharmAthene security holders (subject to potential upward adjustment of up to 337,500 shares).
- Note Consideration: $12,500,000 in 8% convertible notes issued by the Company.
- Milestone Payments: Up to $10,000,000 contingent upon meeting certain conditions.
- Shares Outstanding: Approximately 24,150,000 shares immediately post-merger (excluding redemptions and potential adjustments).
- Redemptions: 1,807,475 shares were elected for conversion into cash from the trust account by shareholders voting against the merger.
- The filing references a Loan and Security Agreement with Silicon Valley Bank and Oxford Finance Corporation (Exhibit 10.20).
- Cash for redemptions was funded from the Company's IPO trust account.
- Note: Specific revenue, profit, cash flow, and margin figures are not provided in this 8-K; they are incorporated by reference from the Definitive Proxy Statement.
Material Changes and Corporate Actions
- Change in Shell Status: The Company ceased to be a shell company upon the closing of the merger.
- Management Changes:
- Resignations: John Pappajohn (Secretary), Derace M. Schaffer (Vice Chairman/CEO), Matthew P. Kinley (President/Treasurer/Director), Edward Berger (Director), and Wayne Schellhammer (Director) resigned from their respective roles.
- Appointments: David P. Wright appointed President and CEO. New directors include James H. Cavanaugh, Elizabeth Czerepak, Steven St. Peter, Joel McCleary, and John Gill.
- Stockholder Structure: Significant ownership by funds affiliated with MPM Capital (16%), HealthCare Ventures VII (14.4%), and Nexia Biotechnologies (6.93%).
Risks, Contingencies, and Unusual Items
Legal Proceedings and Vote Validity:
A critical risk involves the validity of the stockholder vote approving the merger. The number of shares electing conversion was initially misreported. To ensure the merger passed, certain officers, directors, and stockholders purchased an additional 400,000 shares to vote in favor. A stockholder has sought a determination from the Delaware Court of Chancery to affirm the vote's validity. If the court rules the merger invalid, the Company may be required to liquidate trust funds.
Warrant Exercisability:
Outstanding warrants (exercisable at $6.00/share) cannot currently be exercised because the Company has not yet filed a registration statement for the underlying shares. If the merger is deemed invalid, these warrants could expire worthless.
Lock-Up Agreements:
Stockholders receiving merger consideration are subject to lock-up agreements: 50% of shares are released after six months, and the remainder after twelve months.
Unregistered Sales:
"New Investors" purchased 2,429,360 shares in private transactions and received options to acquire up to 1,099,070 additional shares at $0.0001 per share, contingent on the merger's consummation.
Investor Verification Checklist
- Merger Validity: Monitor the status of the Delaware Court of Chancery proceedings regarding the stockholder vote and potential liquidation of trust funds.
- Warrant Registration: Verify the filing and effectiveness of the registration statement required to make outstanding warrants exercisable.
- Debt Obligations: Review the terms of the $12.5M convertible notes and the existing Loan and Security Agreement with Silicon Valley Bank/Oxford Finance.
- Financial Statements: Consult the Definitive Proxy Statement (filed July 16, 2007) for detailed historical and pro forma financial data not included in this 8-K.
- Share Count Adjustments: Confirm the final share count after the resolution of the 1.8M share redemptions and any potential issuance of adjustment shares.